Search research articles
Contact Us
Filters
Showing results (91-100 of 178) with videos related to
Page
of 18
Sort By:
Plos One
|
February 7, 2022
Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer
Florian Heitz, Sotirios Lakis, Philipp Harter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Dominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 26, 2024
Validation and clinical performance of a single test, DNA based endometrial cancer molecular classifier
Amy Jamieson, Marcel Grube, Felix Kommoss, et al.
The Journal of Molecular Diagnostics : JMD
|
October 3, 2022
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling
Carsten Denkert, Marcel Romey, Brad Swedlund, et al.
Archives of Pathology & Laboratory Medicine
|
December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?
Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 2025
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides
Frederik Marmé, Eva I Krieghoff-Henning, Lennard Kiehl, et al.
Gynecologic Oncology
|
April 26, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Benoit You, Charles Anderson, Sabrina Chiara Cecere, et al.
JAMA Network Open
|
April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations
Philip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2023
Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
Nicolò Bizzarri, Majdi Imterat, Robert Fruscio, et al.
Journal of the National Cancer Institute
|
December 28, 2021
Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer
Konstantin Weber-Lassalle, Corinna Ernst, Alexander Reuss, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 178) with videos related to
Sort By:
Page
of 18
Plos One
|
February 7, 2022
Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer
Florian Heitz, Sotirios Lakis, Philipp Harter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Dominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 26, 2024
Validation and clinical performance of a single test, DNA based endometrial cancer molecular classifier
Amy Jamieson, Marcel Grube, Felix Kommoss, et al.
The Journal of Molecular Diagnostics : JMD
|
October 3, 2022
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling
Carsten Denkert, Marcel Romey, Brad Swedlund, et al.
Archives of Pathology & Laboratory Medicine
|
December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?
Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 2025
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides
Frederik Marmé, Eva I Krieghoff-Henning, Lennard Kiehl, et al.
Gynecologic Oncology
|
April 26, 2025
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
Benoit You, Charles Anderson, Sabrina Chiara Cecere, et al.
JAMA Network Open
|
April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations
Philip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2023
Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
Nicolò Bizzarri, Majdi Imterat, Robert Fruscio, et al.
Journal of the National Cancer Institute
|
December 28, 2021
Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer
Konstantin Weber-Lassalle, Corinna Ernst, Alexander Reuss, et al.
Page
of 18